ImpediMed – The Inside Adviser

Stay informed Sign up for our newsletter and be the first to know.

Brilliant Investment Thinking by Advisers for Advisers.

ASX

-0.70%

S&P

-2.64%

AUD

$0.71

Part of The Inside Network

Thinking ahead – ASX MedTech leaders

October 12, 2020 by James Dunn

Here's the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts' consensus target...